3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
30
Prostatic Neoplasms, Castration-Resistant
5
Neoplasm Metastasis
5
Breast Neoplasms
3
Prostate Carcinoma Metastatic to the Bone
2
Neoplasms
2
Hormone Refractory Prostate Cancer
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lung Neoplasms
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Interventions
radium Ra 223 dichloride
1
enzalutamide
1
abiraterone
1
Radium-223
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
radium Ra 223 dichloride
×
Clear all
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled